Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 6;16:101. doi: 10.1186/s13000-021-01163-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — a No significant differences in overall survival (OS) were detected among 20 PTCL-TFH patients, 23 PTCL-NOS, and 38 AITL. b 12 large cell PTCL-TFH patients show significantly worse OS than small cell PTCL-TFH (n = 8; p = 0.045), AITL (n = 38; p = 0.047) and F-TCL (n = 6; p = 0.012). c CMYC+ tumour cells (n = 23) are a poor prognostic factor in 64 patients with TFH+ PTCLs (p = 0.029). d 22 patients with both PD-L1+ tumour cells and R3+ PD-L1+ cells show significantly worse OS than 42 with R1+ and R2+ PD-L1+ cells (p = 0.0004). e 21 patients with both PD-1+ tumour cells and high PD-L1+ group (n + and R3+) show significantly worse prognosis than 43 of the other group (p = 0.005). f 10 patients with both CMYC+ tumour cells and high PD-L1+ group show significantly poorer OS compared with 54 patients in the other groups of TFH+ PTCLs (p < 0.0001)